Zila to Introduce ViziLite Plus in India
24 Febrero 2009 - 9:30AM
Business Wire
Zila, Inc. (NASDAQ:ZILA) today announced that it has selected
Getwell Life Sciences, based in New Delhi, to distribute Zila�s
ViziLite� Plus with TBlue�, a proprietary oral cancer screening
product, throughout India. Financial terms of the agreement were
not disclosed.
�India is obviously a major market that represents an excellent
opportunity for ViziLite Plus. Through our relationship with
Getwell, we plan to aggressively introduce our product all over the
country,� said David Bethune, chairman and CEO of Zila. �We are
working closely with Getwell to gain the necessary regulatory
approvals required by the Indian government in order to begin
selling ViziLite Plus, which we expect to take approximately three
months. Our plan is to offer the most cost effective product
possible in order to reach the millions of Indians that could
benefit from ViziLite Plus.�
�Oral cancer is the most common cancer in India, accounting for
nearly 12% of all cancers detected and 50% to 70% of cancer-related
deaths. The widespread practice of chewing various forms of tobacco
and betel nut and smoking tobacco are the major causes of oral
cancer,� said Suresh Pathak, CEO & Director of Getwell Life
Sciences. �Abundant availability of ready-to-use tobacco pouches
and gutkas are mainly responsible for the rampant use of tobacco,
including by the young and educated. With cancer rates on the rise
in India, the introduction of the new oral cancer screening
product, ViziLite Plus, is particularly important.�
With more than 1.15 billion people, India is the world�s second
most populous country. The Government of India has recently
included early cancer detection in the Cancer Control Program
making it a national health priority.
About Oral Cancer and ViziLite Plus
Oral cancer is the sixth leading cause of cancer worldwide, and
in the U.S., one person dies every hour from the disease. According
to American Cancer Society data, nearly as many women will be
diagnosed with oral cancer as with cervical cancer this year. The
key to reducing the impact of this disease is early detection, yet
prior to the introduction of ViziLite Plus the only screening tools
available were the manual and visual exam, which helps explain why
the mortality and morbidity associated with oral cancer have not
markedly improved in the past 40 years. Worldwide clinical trials
have demonstrated that the conventional visual/tactile examination
may fail to identify up to 40% of cancers and precancers. In other
studies, the addition of ViziLite Plus to conventional examination
has been shown to result in identification of 100% of pathological
lesions. ViziLite Plus, an oral screening technology that utilizes
a chemiluminescent light source (ViziLite) and a patented vital
tissue dye (TBlue), helps dentists and dental technicians identify
and evaluate abnormalities in the mouth that could potentially
harbor pathologic changes. The ViziLite Plus exam takes only
minutes and is totally painless and non-invasive.
Oral Cancer Risk factors:
-- age - adults
-- tobacco use - particularly if combined with heavy alcohol
consumption
-- heavy alcohol consumption
-- excessive sun exposure to the lips
-- sexually transmitted virus exposure (HPV)
A report in the New England Journal of Medicine suggests that
exposure to the sexually transmitted human papillomavirus number 16
(HPV16), causes oropharyngeal cancer (a type of oral cancer), and
may help explain the increasing incidence of the disease in younger
people.
About Getwell Life Sciences Getwell Life Sciences (India)
Pvt. Ltd. is a company owned and managed by technocrats. Over the
past five years the Company has established itself among the front
runners in the business of generic oncology and supportive care
products in India. It has a comprehensive product range and a
professional sales and service staff. The Company plans its foray
into cancer screening and oral healthcare through the launch of
ViziLite Plus. Along with the early detection of oral cancer the
Company also plans to popularize the use of ViziLite Plus in
oncology clinics across India for the early screening of oral
cancer relapse cases.
About Zila, Inc.
Zila, Inc., is a fully integrated oral diagnostic company
dedicated to the prevention, detection and treatment of oral cancer
and periodontal disease. ViziLite� Plus with TBlue�, the company's
flagship product for the early detection of oral abnormalities that
could lead to cancer, is the first and only adjunctive medical
device cleared by the FDA for use in a population at increased risk
for oral cancer. In addition, Zila designs, manufactures and
markets a suite of proprietary products sold exclusively and
directly to dental professionals for periodontal disease, including
the Rotadent� Professional Powered Brush, the Pro-Select Platinum�
ultrasonic scaler and a portfolio of oral pharmaceutical products
for both in-office and home-care use.
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934. These
forward-looking statements are based largely on Zila's expectations
or forecasts of future events, can be affected by inaccurate
assumptions and are subject to various business risks and known and
unknown uncertainties, a number of which are beyond the Company's
control. Therefore, actual results could differ materially from the
forward-looking statements contained herein. A wide variety of
factors could cause or contribute to such differences and could
adversely affect revenue, profitability, cash flows and capital
needs. There can be no assurance that the forward-looking
statements contained in this press release will, in fact, transpire
or prove to be accurate. For a more detailed description of these
and other cautionary factors that may affect Zila's future results,
please refer to Zila's Form 10-K for its fiscal year ended July 31,
2008 and Form 10-Q for the quarter ended October 31, 2008.
For more information about the company and its products, please
visit www.zila.com.
Zila (NASDAQ:ZILA)
Gráfica de Acción Histórica
De Ago 2024 a Sep 2024
Zila (NASDAQ:ZILA)
Gráfica de Acción Histórica
De Sep 2023 a Sep 2024